Skip to content

Released Nov 1, 2018, after the close

10-Q filed Nov 6, 2018, 37 days after period end · 0001162194-18-000104

Q3 2018 · 10-Q
Revenue$28.96M+17.0% vs Q3 2017+9.6% vs Q2 2018
Net Income-$14.75MN/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$0.38N/M vs Q3 2017N/M vs Q2 2018
Gross Profit$15,822,000—
Operating Income-$11,628,000N/M
Operating Cash Flowderived-$4,064,000N/M
Free Cash Flowderived-$4,262,000N/M
Margins · derived
Gross margin54.6%
Operating margin-40.1%+22.9 pt vs Q3 2017
Net margin-50.9%+13.5 pt vs Q3 2017

What the release said

The release

Same quarter

MetricQ3 2018Q3 2017Q3 2016Q3 2015
Revenue$28.96M$24.75M$22.19M$28.64M
Net Income-$14.75M-$15.94M-$19.79M-$9.27M
EPS Diluted-$0.38-$0.46-$0.68-$0.32

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR